|
Luke Pase
Chief Technologist Officer
Anocca AB
Stockholm
Sweden
|
"Dr. Luke Pase is the Chief Technology Officer at Anocca AB, bringing over 20 years of experience in genetics, molecular immunology, synthetic biology, and cell engineering. He has utilized a wide array of gene modifying tools across multiple organisms and mammalian cells at scale.
Luke was among the first to join Anocca AB a decade ago, playing a pivotal role in establishing the company's specific mammalian cell engineering workflows. He is a key inventor behind the company’s prioprietary technology platform. In his current role, Luke oversees the R&D TCR platform, which focuses on the identification, characterization and de-risking of a comprehensive library of TCR assets. These TCR assets target a variety of cancer and viral antigens, preparing them for clinical development. Additionally, he designs and evaluates non-viral gene editing strategies for the scale-out manufacture of TCR-T cell therapeutics
"
Luke was among the first to join Anocca AB a decade ago, playing a pivotal role in establishing the company's specific mammalian cell engineering workflows. He is a key inventor behind the company’s prioprietary technology platform. In his current role, Luke oversees the R&D TCR platform, which focuses on the identification, characterization and de-risking of a comprehensive library of TCR assets. These TCR assets target a variety of cancer and viral antigens, preparing them for clinical development. Additionally, he designs and evaluates non-viral gene editing strategies for the scale-out manufacture of TCR-T cell therapeutics
"